Description
Alnylam Pharmaceuticals: The Groundbreaking ATTR Amyloidosis Expansion That’s Turning Heads!
Alnylam Pharmaceuticals Inc., a leader in genetic medicine, reported strong results for the fourth quarter and full year 2024, achieving significant financial milestones and robust pipeline advancements. The company announced net product revenues exceeding $1.6 billion, representing a notable 33% growth from the previous year. This performance was driven by the continued uptake of their therapeutics for hereditary transthyretin[1]mediated (hATTR) amyloidosis and other rare diseases.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
